ValiRx PLC (AIM: VAL) has received notice that the European Patent Office intends to grant a second patent covering the cancer-killing peptide being developed by its majority-owned subsidiary Cytolytix.
The patent covers polyleucine-based peptides as anti-cancer agents and follows the grant in May of a separate European patent protecting the nanoparticle formulation used to deliver the peptide.
The expanded patent protection strengthens Cytolytix’s intellectual property position as ValiRx pursues licensing, pharmaceutical partnerships and non-dilutive funding.
Cytolytix’s technology works by disrupting cancer cell membranes, directly killing tumour cells while releasing antigens that may stimulate an immune response. Its lead target is triple-negative breast cancer, an aggressive cancer with limited targeted treatment options.
ValiRx has also filed a further patent application covering a second-generation lipid-based delivery system, supported by data demonstrating immunogenic cell death in triple-negative breast cancer cells.
Chief Executive Mark Eccleston said the growing range of proprietary formulations could enable different routes of administration across both human and veterinary cancer markets.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Leave a comment